Navigation Links
Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
Date:8/3/2010

tatements include statements regarding the anticipated action date for the FDA to complete its review of the Contrave NDA, the potential for, and timing of, approval for Contrave and the Company's belief that a weight management strategy, addressing both the biological and behavioral drivers of obesity, can be successful and may offer patients lasting success. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave; reliance on third parties to assist with the development of Contrave; the potential for adverse safety findings relating to Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 10, 2010 and is available from the SEC's website (www.sec.gov) and on our website (
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
4. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
5. Cornerstone Therapeutics Announces Collaboration with The Cough Company
6. Hepatitis C Therapeutics Market - Taiwan
7. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
8. Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics
9. MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
10. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
11. Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... 7, 2007 - REGENERX,BIOPHARMACEUTICALS' (AMEX: RGN), www.regenerx.com ... the 2007 Association for Research in,Vision and ... May 9th to discuss TB4's ability to ... process closely,associated with inflammation that, if not ...
... TSX-V: PGA, VANCOUVER, May 07, 2007 /PRNewswire-FirstCall/ - ... results from its Phase I/II study of PAC-113, ... and active,in the treatment of oral Candida infection ... of care. Based on these results,the Company plans ...
Cached Medicine Technology:Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting 2Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting 3Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 2Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 3Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 4Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 5
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... 17 Clarent Hospital Corporation ... 12, 2007, the Company,s Board ... cash distribution to stockholders of ... is payable on October 31, ...
... 17 The Channel Islands,Alzheimer,s Institute recently received ... be received in four payments of $30,000,each beginning ... Institute is located on the campus of,California State ... donation are at least two student research,scholarships for ...
... Explanations and Insightful Tips for Finding ... Affordable Health Insurance for Your Family, SAN ... a leading source for online,health insurance quotes and ... library of consumer resources: the,Family Health Insurance Guide. Inspired ...
... Prudence Hall,founder of The Hall Center in Santa Monica, ... health of her patients. It wasn,t until she became,immersed ... started investigating her birth control patients more carefully.,"I was ... old patients on the,pill, had hormone levels that were ...
... establishing the Dyslexia Research Laboratory at Beth Israel Deaconess ... dramatic transformation in thinking among both scientists and the ... a host of explanations offered to explain dyslexia, says ... BIDMC whose work has played a key role in ...
... food is needed, study suggests , , WEDNESDAY, Oct. 17 ... to blame, research suggests. , Scientists from the University ... dopamine, a brain chemical that helps make eating and ... more food. , "We weren,t studying obesity, per se, ...
Cached Medicine News:Health News:Channel Islands Alzheimer's Institute Receives $120,000 Donation 2Health News:Health Insurance Finders Debuts A Comprehensive Guide to Family Health Insurance 2Health News:Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients 2Health News:Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients 3Health News:BIDMC Dyslexia Research Lab celebrates 25th anniversary 2Health News:Genes Might Help Drive Overeating 2Health News:Genes Might Help Drive Overeating 3
... is a safe, non-surgical process that ... tighten skin and reverse the signs ... dermis to cause collagen contraction while ... In addition, Titan can stimulate long-term ...
... The smallest, lightest, smartest choice , ... or neurological, ... environment. But will the device ... on its signal quality? Will the battery last? Is it comfortable, ...
... The modular AU5400 is a high-volume analyzer ... productivity of the AU5200 analyzer and the ... automates and consolidates chemistry-immuno testing with up ... to 6,600 tests per hour. Choose from ...
... the quantitative determination of Erythropoietin (EPO) in human ... diagnostic use, as an aid in the diagnosis ... the administration of recombinant erythropoietin as a biologic ... erythropoietin assay may be used also to aid ...
Medicine Products: